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The prevalence of ideal cardiovascular health (CVH) among adults in the United States is low and decreases
with age. Our objective was to identify specific age windows when the loss of CVH accelerates, to ascertain
preventive opportunities for intervention. Data were pooled from 5 longitudinal cohorts (Project Heartbeat!,
Cardiovascular Risk in Young Finns Study, The Bogalusa Heart Study, Coronary Artery Risk Development in
Young Adults, Special Turku Coronary Risk Factor Intervention Project) from the United States and Finland from
1973 to 2012. Individuals with clinical CVH factors (i.e., body mass index, blood pressure, cholesterol, blood
glucose) measured from ages 8 to 55 years were included. These factors were categorized and summed into a
clinical CVH score ranging from 0 (worst) to 8 (best). Adjusted, segmented, linear mixed models were used to
estimate the change in CVH over time. Among the 18,343 participants, 9,461 (52%) were female and 12,346
(67%) were White. The baseline mean (standard deviation) clinical CVH score was 6.9 (1.2) at an average age of
17.6 (8.1) years. Two inf lection points were estimated: at 16.9 years (95% confidence interval: 16.4, 17.4) and at
37.2 years (95% confidence interval: 32.4, 41.9). Late adolescence and early middle age appear to be inf luential
periods during which the loss of CVH accelerates.
adolescence; cardiovascular epidemiology; cardiovascular health; cohort studies; longitudinal studies;
prevention; risk factors

Abbreviations: BMI, body mass index; BP, blood pressure; CARDIA, Coronary Artery Risk Development in Young Adults; CVH,
cardiovascular health; STRIP, Special Turku Coronary Risk Factor Intervention Project; Young Finns, Cardiovascular Risk in
Young Finns Study.

Heart disease remains the leading cause of death in the
United States, and the current prevalence of ideal cardiovascular health (CVH) among adults in the United States
is less than 5% (1, 2). Ideal CVH is a concept, defined
by the American Heart Association, and includes 4 health
factors (body mass index (BMI), blood pressure (BP), total
cholesterol, and fasting blood glucose) and 3 health behaviors (smoking, physical activity, and diet) (2). Ideal CVH has
been linked to a broad range of improved health outcomes,
including greater longevity and quality of life, and lower risk
for heart disease, incident cancer, and dementia (3). Ideal
CVH prevalence decreases with age, but whether declines
are consistent across the life course is unknown. Identifying

if there are ages when the rate of CVH decline accelerates
could facilitate better targeting of preventive efforts to these
periods and understanding of the causes and drivers of loss of
CVH, which may be due to specific developmental periods
across the life course.
Recent advances in estimation of change points allow us
to estimate when decline in CVH begins to accelerate across
the life course. Previous studies have looked at overall patterns or trajectories of CVH over time to determine how the
trajectories correspond to future risk and characterize which
children may be more likely to be in specific risk categories;
these studies have provided important information about
risk stratification (4, 5). The present study expands on this
2384
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same examination were summed to create a clinical CVH
score. This score ranged from 0 to 8, with higher CVH score
indicating better CVH. This score is associated with the
future risk of heart disease: maintaining a higher score is
associated with less risk (4).
CVH behaviors

CVH behaviors (i.e., smoking, diet, and physical activity)
were not measured consistently across follow-up and thus
were not included in the clinical CVH score. However,
baseline behaviors were captured in each cohort and were
categorized as ideal or not ideal on the basis of the American
Heart Association criteria (Web Table 1) to describe the
characteristics of the sample in Table 2 (2, 13).

METHODS
Cohorts and participants

This study included 18,343 individuals from 5 cohorts:
Project HeartBeat! (6), Cardiovascular Risk in Young Finns
Study (Young Finns) (7), The Bogalusa Heart Study (8),
Coronary Artery Risk Development in Young Adults (CARDIA) (9), Special Turku Coronary Risk Factor Intervention
Project (STRIP) (10). Details of harmonizing these cohorts’
data are described elsewhere (4). In brief, clinical measurements were collected for each cohort at in-person examinations and questionnaires were used to collect demographic
and behavioral data over varied ages and lengths of time. By
including cohorts that spanned overlapping age windows, we
could cover a wider range, from ages 8 through 55 years.
Participants were included in the analysis if they had at
least 1 clinical CVH score (all 4 clinical CVH components
measured at the same examination), as described the next
section, CVH factors (Web Figure 1) (available at https://
doi.org/10.1093/aje/kwab149). Parental education data, categorized as years of education, were collected as a proxy for
socioeconomic status.
CVH factors

CVH factors available from all studies included BMI, BP,
and lipid and fasting glucose levels. BMI was calculated
from measured weight (in kilograms) and the square of the
height (in meters). Before calculating the CVH score, BMI
was converted to an age- and sex-specific percentile for those
younger than 20 years, using the Centers for Disease Control
and Prevention calculation (11).
Systolic and diastolic BP were measured in all cohorts at
every examination. BP was converted to percentile values
for those younger than 18 years, using the pediatric hypertension guidelines published in 2017 (12). Levels of fasting
serum lipids and fasting blood (plasma or serum) glucose
were measured at multiple examinations for each cohort.
Each BMI, BP, fasting glucose, and total cholesterol
observation was considered ideal, intermediate, or poor, on
the basis of American Heart Association criteria (Table 1)
(2, 4). To create a CVH score, points were assigned for the
levels of each factor: 0 for poor, 1 for intermediate, and 2
for ideal. Points from the 4 CVH factors measured at the
Am J Epidemiol. 2021;190(11):2384–2394

Statistical analysis

Demographic variables, CVH factors, CVH behaviors, and
parental education measured at each participant’s baseline
examination were described and stratified by sex (Table 2)
and by age (Web Table 2). We estimated the age at which
distinct change points occurred in the mean clinical CVH
score from age 8 years through age 55 years, using piecewise
linear regression extended to a longitudinal framework in
the unpublished R (R Foundation for Statistical Computing,
Vienna, Austria) function “segmented.lme” (14). This approach allows for the estimation of interpretable parameters
such as slopes and change points.
First, the mixed model was fit with a random participant
intercept and slope and adjusted for race, sex, and cohort
using “nlme” in R (15). Next, we implemented an iterative
procedure to estimate the change point(s) of the mixed
model, using “segmented.lme.” The change point(s) and
their asymptotic 95% confidence intervals were estimated
using a maximum likelihood approach. After the change
point(s) were estimated, linear, quadratic, and cubic mixed
models, and segmented linear mixed models with 1 and 2
change points were compared. The best fit was determined
using Akaike Information Criteria, Bayesian Information
Criteria, and likelihood ratio tests (Web Table 3). Because
there was a significant interaction among age, race, and sex
(P < 0.001) in the initial mixed model, analyses were stratified by sex, and models were fit using the same procedure.
After estimating the change point(s), we tested the difference between the slopes in each age window (8.0–16.9 years,
17.0–36.9 years, and 37.0–55.99 years) by sex. The change
in CVH score over time was modeled as a multivariable,
piecewise linear regression model with 2 knots (determined
by the aforementioned change point estimates), adjusting
for race and cohort. Interaction terms between age and sex
were included in the model to test for sex differences in the
magnitude of change in CVH over time.
To further test the robustness of our models, we calculated
means at ages 8, 17, 37, and 55 years for each component of
the CVH score separately (i.e., BMI, BP, and fasting glucose
and total cholesterol levels) using their original continuous values (e.g., continuous systolic BP in millimeters
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concept by decomposing risk over time to determine specific
periods or ages, which has not been quantitatively assessed
in previous studies.
In this study, to identify opportunities to promote and
maintain ideal CVH throughout the life course, we sought
to estimate influential age windows when the rate of decline
in CVH changes at the population level. In addition to
identifying these influential change points, we wanted to
determine whether there are sex differences in the rate of
change between change points, as well as how the individual
metrics changed over time. We hypothesized CVH declines
are not consistent across the life course and there is at least
1 age when the rate of decline significantly changes.
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≥126
≥126
>95th

RESULTS

Abbreviations: DBP, diastolic blood pressure; SBP, systolic blood pressure.
a Weight (kg)/height (m)2

>95th
Poor

≥30.0

≥220

≥220

SBP ≥140 or
DBP ≥90

100–125 or treated
to < 100
100–125 or treated
to < 100
90th–95th or
SBP ≥120 or
DBP ≥80
SBP 120–139 or
DBP 80–89, or
treated to <120/80
185–219 or treated 185–219 or treated
to < 185
to <185
85th–95th
25.0–29.99
Intermediate

<100, unmedicated <100, unmedicated
<90th
<120/80,
unmedicated
<185, unmedicated <185, unmedicated
<85th
<25.0
Ideal

Age <20 Years
Age ≥20 Years
Age <18 Years,
percentile
Age ≥18 Years
Age <20 Years

Blood Pressure, mm Hg
Total Cholesterol, mg/dL

Age ≥20 Years
Age <20 Years,
percentile
Age ≥20 Years
Health
Category

Body Mass Indexa

of mercury rather than poor, intermediate, or ideal BP). Although age- and sex-specific percentiles were used to score
BMI and BP into ideal categories for persons younger than
20 years (for BMI) and 18 years (for BP), continuous metrics
were used to calculate means for the purposes of continuity
across the full age range. We used t tests to determine if
there was a significant difference between the means for
males and females at each age.
Analyses were performed using SAS, version 9.4 (SAS
Institute Inc, Cary, North Carolina) and R, version 3.3.3
(16) using the nlme package (15) and an extension of the
segmented package written by Muggeo et al (14, 17) for use
with linear mixed models. Statistical significance was set a
priori at P < 0.05.

Among the 18,343 participants in our sample, 9,461
(52%) were female and 12,346 (67%) were White. At the
baseline examination, 10,463 (64%) had ideal smoking
status, whereas only 16% had ideal diet or ideal physical
activity scores. Mean age at baseline was 17.6 (standard
deviation, 8.1) years. The mean clinical CVH score at
baseline was 6.9 (standard deviation, 1.2) out of a possible
8.0 (Table 2).
In modeling clinical CVH scores over time, the adjusted,
segmented, linear mixed model with 2 change points and
random intercept and slope provided the best fit to the data
compared with other models (Web Table 3). Change points
in unadjusted models were estimated at 17.3 and 35.1 years
(95% confidence intervals (CI): 16.8, 17.8; and 32.3, 37.9,
respectively), as shown in Figure 1A. The adjusted model
had change points at 16.9 (95% CI: 16.4, 17.4) and 37.2
(95% CI: 32.5, 41.9) years. This second inflection point’s
uncertainty, causing a somewhat wider confidence interval,
reflected a much smaller acceleration in the rate of decline.
Before the first change point in both the unadjusted and
adjusted models, beginning at age 8 years in the present
data, the rate of decline was close to 0 (0.01 points/year;
95% CI: −0.004, 0.02 in the adjusted model). After the first
change point, the rate of decline significantly increased to
−0.07 points/year (95% CI: −0.08, −0.07). At that rate, an
individual would lose 1.5 points in their clinical CVH score
in the 20-year span between ages 17 and 37 years. After age
37 years, the rate of decline increased further to −0.08 (95%
CI: −0.09, −0.08) points/year (Figure 2).
The stratified models determining change points for males
and females did not differ significantly from each other or
the overall estimates (male, unadjusted (Figure 1B); male,
adjusted: 16.93 (95% CI: 16.25, 17.61) and 35.69 (95%
CI: 33.09, 38.29); female, unadjusted (Figure 1C); female,
adjusted: 16.71 (95% CI: 15.94, 17.47) and 36.06 (95% CI:
34.62, 37.49)). However, the slopes of the various segments
by sex were significantly different in all 3 age windows:
8 to < 17 years, 17 to < 37 years, and 37 through 55
years (Table 3). Before age 17 years, female CVH held
steady while male CVH decreased 0.01 points/year (95%
CI: −0.02, −0.01; for difference between sexes, P = 0.001).
Between ages 17 and 37 years, CVH declined at a faster
Am J Epidemiol. 2021;190(11):2384–2394
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Table 1. Clinical Cardiovascular Health Score Components, Cardiovascular Health Pooled Cohort, 1973–2012
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Table 2. Demographic Characteristics, Clinical Measures, and Covariates at Each Individual’s First Examination, by Sex, Cardiovascular
Health Pooled Cohort,a 1973–2012
Female (n = 9,461)

Mean (SD)
White race
Age, years

No.

%

6,058

68.2

17.4 (8.1)

Mean (SD)

No.

%

6,288

66.5

17.4

17.8 (8.1)

Cohort
Young Finns

1,486

16.7

1,650

201

2.3

208

2.2

CARDIA

2,315

26.1

2,783

29.4

Bogalusa Heart Study

4,628

52.1

4,582

48.4

252

2.8

238

2.5

62.4

5,541

64.8

Project HeartBeat!

STRIP
Clinical measures
BMIb

21.3 (4.9)

21.5 (5.5)

BMI %, by age and sexc

52.8 (29.9)

53.5 (30.1)

SBP, mm Hg

109.5 (13.1)

105.9 (11.1)

SBP %d

47.7 (27.0)

50.2 (26.8)

DBP, mm Hg

59.1 (15.1)

59.4 (13.0)

DBP %d

24.9 (22.4)

28.9 (24.1)

Total cholesterol, mg/dL

169.8 (34.0)

173.2 (33.1)

Fasting glucose, mg/dL

85.9 (12.7)

83.0 (14.4)

Ideal behavior scoree
Smoking

4,922

Diet

1,088

23.6

1,793

32.6

Physical activity

1,781

38.3

1,179

22.4

231

3.6

313

4.3

Maternal educationf
≤6 years
7–9 years

971

14.9

1,131

15.5

10–12 years

2,869

44.1

3,164

43.4

13–16 years

1,947

29.9

2,176

29.8

483

7.4

508

7.0

>16 years (graduate school)
Paternal education,

yearsf

≤6

270

4.7

361

5.7

7–9

1,045

18.3

1,215

19.0

10–12

2,348

41.1

2,574

40.3

13–16

1,609

28.1

1,719

26.9

447

7.8

514

8.1

>16 (graduate school)
Clinical CVH score

6.8 (1.3)

7.0 (1.2)

Abbreviations: BMI, body mass index; CARDIA, Coronary Artery Risk Development in Young Adults; CVH, cardiovascular health; DBP,
diastolic blood pressure; SBP, systolic blood pressure; SD, standard deviation; STRIP, Special Turku Coronary Risk Factor Intervention Project,
Young Finns, Cardiovascular Risk in Young Finns Study
a The CVH pooled cohort comprised participants in the Bogalusa Heart Study, CARDIA, Project HeartBeat!, STRIP, and Young Finns.
b Weight (kg)/height (m)2 .
c The BMI% calculation was only available for those who were < 20 years old at baseline. In analytical sample BMI%, n = 11,777;
d SBP%, and DBP% data were only available for those who were < 18 years old at baseline. In the analytic sample BP%, n = 10,627.
e Behavior scores were not captured at the first visit for every participant; these scores represent their first available score for that behavior.
f Parent education data were not available for all individuals.
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Male (n = 8,882)
Characteristic
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A)
8

Clinical CVH Score

4

2

Sex
Male
Female

0
8

15

25

35
Age, years

B)

45

55

C)
8
Clinical CVH Score

Clinical CVH Score

8

6

4

2

0

6

4

2

0
8

15

25
35
Age, years

45

55

8

15

25
35
Age, years

45

55

Figure 1. Plots of unadjusted segmented mixed models (fixed effects only), cardiovascular health (CVH) pooled cohort, 1973–2012. A) Overall
model (change points: 17.3 and 35.1; 95% confidence intervals (CIs): 16.8, 17.8 and 32.3, 37.9, respectively). Stratified models: B) males (change
points: 17.1 and 37.2; 95% CIs: 16.9, 18.3 and 33.7, 40.6, respectively) and C) females (change points: 16.8 and 35.6; 95% CIs: 16.1, 17.6 and
34.3, 36.9, respectively). (For illustrative purposes, data points from 50 randomly selected participants are shown).

rate for men than for women (−0.09 vs. −0.06; P < 0.001).
After age 37 years, CVH declined more rapidly for women
than men (−0.09 vs. −0.07; P < 0.001), which suggests a
different pattern of change by sex. Models stratified by sex
and race were not substantively different from the models
stratified by sex only (Web Table 4 and Web Figure 2).
The sex-specific means at each influential age (i.e., 8,
17, 37, and 55 years) help explain the differences in the
change in CVH score over time (Table 4 and Web Figure 3).
Behavioral metrics, diet, physical activity, and smoking data
were collected less frequently than were the clinical metrics;
mean scores (poor (0) to ideal (2)) are shown in Web Table 5.
BMI increased steadily for both males and females over
time; however, the difference between the 2 sexes was not

significant at any of the 4 ages. The change in BMI over time
was consistent with the change in overall score over time
in that it remained at ideal levels at ages 8 and 17 years,
declined to intermediate by age 37 years, and to poor by
age 55 years. BP started out similarly for males (97/44 mm
Hg) and females (97/45 mm Hg). Although mean systolic
and diastolic BP both increased for each sex, they remained
at ideal levels through age 55 years. Males had a steeper
increase in systolic BP than females before age 17 years
(+6.0 mm Hg), but after holding relatively steady between
ages 17 and 37 years, increased less between ages 37 and 55
years, compared with females (5.2 vs. 7.9 mm Hg). Males
and females had a similar increase in diastolic BP before
age 17 years. Between ages 17 and 37 years, diastolic BP
Am J Epidemiol. 2021;190(11):2384–2394
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−0.09, −0.09

−0.09

0.02

17.0–36.9: male − female

37.0–55.9: male − female
0.02, 0.03

−0.03, −0.03

<.001

<.001

0.001

<.001

<.001

<.001

<.001

<.001

0.83

0.04

<.001

<.001

P Value

0.38

−0.59

−0.13

−1.24

0.02

−0.03

−0.01

−0.07

−0.01
−0.09

−1.8

−0.09

−0.06

0.00

0.05

7.00

6.95

Mean

−0.12

−1.63

−1.21

0.01

Total  Over
Segment

0.01, 0.03

−0.03, −0.03

−0.02, −0.01

−0.07, −0.06

−0.09, −0.09

−0.02, 0.00

−0.09, −0.09

−0.06, −0.06

0.00, 0.01

0.00, 0.11

6.94, 7.06

6.89, 7.00

95% CI

<.001

<.001

<.001

<.001

<.001

<.001

<.001

<.001

0.38

0.06

<.001

<.001

P Value

0.38

−0.59

−0.13

−1.25

−1.79

−0.12

−1.63

−1.2

0.01

Total  Over
Segment

Abbreviations: CVH, cardiovascular health; , change in, or difference.
a Clinical CVH score ranges from 0 to 8, with 8 being the most ideal.
b CVH pooled cohort comprised participants in the Bogalusa Heart Study, Coronary Artery Risk Development in Young Adults, Project HeartBeat!, Special Turku Coronary Risk Factor
Intervention Project, and Cardiovascular Risk in Young Finns Study.
c Adjusted for age at baseline, race, and cohort. Numbers presented are for Black individuals from the Bogalusa Heart Study (Bogalusa, Louisiana).

−0.01
−0.03

8.0–16.9: male − female

−0.02, −0.01

−0.07, −0.06

−0.07

37.0–55.9

Difference in segment-specific slope between
sexes, by age group, years

−0.02, −0.01
−0.09, −0.09

−0.01
−0.09

8.0–16.9

17.0–36.9

Age group, years, male

37.0–55.9

−0.01, 0.01
−0.06, −0.06

0.00
−0.06

17.0–36.9

0.00, 0.11

7.11, 7.19

7.05, 7.13

8.0–16.9

Age group, years, female

Segment-specific slope, /year

0.06

7.15

95% CI

Adjustedc
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Difference in mean CVH score for 8-year-old
children between sexes

7.09

Male

Mean

Female (referent)

Mean CVH score for 8-year-old children

CVH Outcome

Unadjusted

Table 3. Mixed Model Parameter Estimates of Mean Clinical Cardiovascular Health Scorea Over Time, by Sex, Cardiovascular Health Pooled Cohort,b 1973–2012

Influential Periods in Cardiovascular Health
2389

167.6
80.7
27.5

Total cholesterol, mg/dL

Fasting blood glucose, mg/dL

BMIb

Am J Epidemiol. 2021;190(11):2384–2394
90.1

Total cholesterol, mg/dL

Fasting blood glucose, mg/dL

18

33.1

11

14.4

7.2

8.0

27.9

12.0

8.8

3.1

SD

96.3

193.3

75

116.2

27.6

82.4

164.2

44.1

96.8

17.0

Mean

9.0

25.8

10.9

8.3

2.9

SD

25.9

40.5

10.4

12.9

5.4

6.1

11.9

4.3

6.5

0.1

117.6
72.6

5.1 to 7.9c
5.4c

201.7
95.9

8.1 to 15.7c
3.8 to 8.5c

3.2 to

31.4

81.6

163.3

−0.5 to 0.7

0.9 to

−6.1 to −0.6c

−3.4
1.8

−2.1 to 0.2

−1.0
2.6c

−0.6 to 1.2
61.1

22.2
110.7

−0.5 to 0.1

−0.2

Mean

15.8

36.3

11.2

15.9

7.7

8.2

30.6

8.6

9.0

4.5

SD

Female

0.3

95%CI

Difference in Mean
(μ Male − μ Female )
Difference

37-Year-Olds

Male

104

182.4

73.9

121.4

30.3

86

151.1

59.6

117

22.3

Mean

8.4

28.2

10.3

11.7

4.1

SD

6.1

21.9

35.9

10.3

15.9

8

−19.3

1.3

3.7

−1.1

4.4

−12.2

−1.5

6.3

0.1

3.6 to 12.4c

−27.4 to −11.2c

−1.1 to 3.7

0.2 to 7.3c

−2.6 to 0.4

3.5 to 5.2c

−15.2 to −9.2 c

−2.4 to −0.5 c

5.2 to 7.4c

−0.3 to 0.5

95%CI

Difference in Mean
(μ Male − μ Female )
Difference

55-Year-Olds

Male

17-Year-Olds
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Abbreviations: BMI, body mass index; BP, blood pressure; CI, confidence interval; SD, standard deviation.
a CVH pooled cohort comprised participants in the Bogalusa Heart Study, Coronary Artery Risk Development in Young Adults, Project HeartBeat!, Special Turku Coronary Risk Factor
Intervention Project, and Cardiovascular Risk in Young Finns Study.
b Weight (kg)/height (m)2 .
c P < 0.05 for t test.

70.7
181.4

Diastolic BP, mm Hg

109.7

45.1

Diastolic BP, mm Hg

Systolic BP, mm Hg

17.2
96.5

Systolic BP, mm Hg

Mean

Female

BMIb

Clinical Metric

8-Year-Olds

Age Group

Table 4. Mean Values of Each Clinical Metric at the Change Points, by Sex, CVH Pooled Cohort,a 1973 to 2012
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Figure 2. Adjusted segmented mixed model, by sex, cardiovascular
health (CVH) pooled cohort, 1973–2012. The reference group, Black
males and females from Bogalusa Heart Study (1973–2010), is
shown here. Dashed vertical lines indicate the knots at 17 and 37
years. Clinical CVH score ranges from 0 to 8, with 8 being the most
ideal.)

in men increased and then decreased slightly after 37 years,
whereas in women, BP increased less steeply between ages
17 and 37 years and continued to increase after age 37 years.
Mean total cholesterol and fasting blood glucose levels
were significantly different by sex at all 4 ages. Total cholesterol levels in females declined from ages 8 to 17 years (168
mg/dL to 163 mg/dL) and then increased at age 37 years
and increased again to reach intermediate levels at age 55
years. Total cholesterol declined in males from ages 8 to 17
years (164–151 mg/dL) increased to 193 mg/dL at age 37
years, and decreased to 182 mg/dL at age 55 years. Total
cholesterol levels were in males were lower than in females
at all ages except 37 years. Blood glucose levels in males
increased more than in females in every age period. Blood
glucose levels in females consistently increased over time,
from 80.7 mg/dL at age 8 years to 95.9 mg/dL at age 55
years.
In a sensitivity analysis including 14,422 individuals with
complete parental education data, results were similar between the models with and without adjustment for parental
education (16.2 years (95% CI: 15.5, 16.8) and 39.8 years
(35.8, 43.8) without adjustment for parental education compared with 16.1 years (95% CI: 15.4, 16.7) and 39.3 years
(35.5, 43.0) with adjustment).

DISCUSSION

Within this pooled cohort, there were influential periods
in adolescence and adulthood when the loss of clinical CVH
was accelerated. The largest acceleration in the age-related
Am J Epidemiol. 2021;190(11):2384–2394

loss of clinical CVH occurred at the first change point, at
approximately age 17 years. A second, less dramatic acceleration in the age-related decline in clinical CVH occurred at
the second change point, in middle age at age 37 years. These
ages (approximately 17 and 37 years) appear to coincide
with social and developmental transitions, providing unique
insight to the development of preventive interventions tailored to these specific phases in life (18). CVH score slopes
between change points as well as the patterns of change
for the individual metrics comprising the score differed
by sex, suggesting the potential importance of sex-specific
interventions.
At age 17 years, adolescents typically gain increased independence from their parents and transition from pediatric
to adult health care practitioners. Many adolescents leave
their provider’s practice between ages 15 and 22 years,
mainly because of aging out or completely dropping out of
primary care (19, 20). This poses challenges for intervention,
due to interrupted continuity of care. Males tend to have a
longer gap in care than females (21). Changes in schedules,
school, and jobs may interfere with meeting guidelines for
healthy sleep, physical activity, and diet (22). There is also a
large shift in personal responsibility, greater financial independence, with access to tobacco, greater personal choices
around food selection, alcohol use, and physical activity at
this time. These behaviors are important for achieving and
maintaining ideal CVH (2). We observed low mean scores
for diet among persons aged 17 years, suggesting diet may
be an important lifestyle behavior to potentially target for
intervention.
At approximately age 37 years, adults transition from
young adulthood to middle age. The increasing personal,
professional, and social pressures encountered during this
phase of life may additionally compete with adherence to a
healthy lifestyle, leading to diminished levels of clinical risk
factors. Employment-based wellness programs could help
facilitate maintenance of CVH during this period.
Although the second change point at age 37 years was
slight in the overall model, there was a significant difference
by sex, illustrating changes men and women experience over
time. Our results show that although women maintained a
higher CVH score through age 37 years, their rate of decline
was significantly greater than that of men from ages 37 to 55
years. These results support well-documented data showing
that men and women differ in their trajectories regarding
CVH risk factor development over time (22). Although
much remains unknown about CVH during and after pregnancy in women, pregnant women between the ages of 20
and 44 years are significantly less likely to maintain ideal
CVH than are nonpregnant women in the same age range
(23). The second change point falls squarely during women’s
reproductive years and could be a contributing factor in the
difference between men and women during this time. In
addition to the difference in CVH decline, there are also
differences in health care use by sex (24, 25). Men are
less likely than women to use health care services or make
preventive care visits despite declining health comparable to
that of women (25).
Our findings on the age-related changes of individual
CVH metrics complement prior work. Specifically, in most
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we did not have menopausal status available to us from every
cohort; therefore, these biological changes were not included
in our analysis.
In conclusion, adolescence and young adulthood are key
age windows when age-related loss of clinical CVH greatly
accelerates. Trends in CVH are not consistent by sex, and
identification of specific age-windows offers an opportunity for personalized preventive intervention. Additional
research identifying the specific factors leading to accelerated loss of CVH in adolescence and middle adulthood is
needed. The creation of personalized interventions targeted
to these critical age windows may offer new tools to preserve
ideal CVH throughout the life course.
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cross-sectional and cohort studies, researchers reported that
BMI increases with age, possibly leveling out in older age
(26–32). Although trends in BMI over time in this study did
not significantly differ by sex, other authors have suggested,
and we concur, that, ideally, intervention should differ for
men and women (26). For example, Li et al. (33) concluded
that high or increasing BMI at any life stage is associated
with a high adult BP. Although BP increased over time in
our data, it remained, on average, higher in men than women
at most points after age 8 years (33). These 7 metrics are
synergistic in children and young adults with comorbidities
(34). Risk behaviors are interrelated—intervention in one
can affect another (22).
We know that risk of cardiovascular disease is established
long before middle age (35), and with primary and primordial prevention, cardiovascular disease can be prevented
(36). The World Health Organization strongly recommends
primordial and primary prevention of major known risk factors for noncommunicable diseases such as cardiovascular
disease to begin early in life (37). Longitudinal analyses
of CVH have shown that maintaining CVH from childhood
onward reduces the risk for cardiovascular disease in adulthood (4, 5).
Our approach to determining influential age windows
when loss of CVH accelerates has several strengths, including the large data set with multiple observations for individuals from childhood through middle age. The method for
determining change points accounts for repeated measures
within individuals, and we used a likelihood-based approach
that does not require any prior assumptions (14). In 2 of
the 5 cohorts in this pooled cohort analysis, all cohort
members were White; therefore, a limitation of our work
is that we were unable to estimate differences in change
points or slopes by race without essentially performing
cohort-specific analyses. Although we attempted to deal
with cohort-specific differences by adjusting all models by
cohort, there have been changes over time in standards
of care and of public health messaging that may differ
between and within the United States and Finland over
time. Studies will be needed to examine how changes in
clinical, behavioral, and cultural factors may affect these
influential periods. Patterns of change in CVH may differ
within a population. However, in multiple studies on CVH
trajectories, a decline in CVH has been reported to occur
during childhood and early adolescence, and there appears to
be a change point near age 17 years for all trajectory groups
(4, 5); these findings support the population-level influential
age windows we estimated in the present study. Reviewing
the means in each metric by age and sex, we were not able
to take medication use into account, as is done in the CVH
score. So trends in BP and levels of cholesterol and blood
glucose may appear to be attenuated because of medications
used to control these factors. In addition, data on CVH
behaviors are sparse, particularly for younger ages, so we
were not able to estimate change points in the full CVH score
including these observations. Our data begin at age 8 years;
therefore, we cannot generalize from these data how and
when changes in overall CVH may occur in children younger
than 8 years, but this should a topic of future investigation.
Although we did estimate change points separately by sex,
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